Companion Diagnostics Market to reach USD 21.15 billion by 2032, with a growing CAGR of 11.9%.
The market for companion diagnostics is on the rise, and this is observed to be fuelled by the increasing prevalence of cancer globally, particularly the steady growth in demand for personalized medicine. Although the cancer rates continue growing relentlessly, such diagnostics are fast gaining acceptance because of the critical role they play in providing tailored treatment solutions ensuing from individual patient profiles. Advances in biomarker research directly advance precision diagnostics and particularly help oncology through more accurate detection of individual mutations and corresponding therapies.